11:17 AM EST - HLS Therapeutics Inc. : Reported today on the presentation of REDUCE-IT® Coronary Artery Bypass Grafting analysis at the American Heart Association's Virtual Scientific Sessions 2020, being held virtually from November 13-17, , adding to the growing body of knowledge on the clinical impact of VASCEPA® (icosapent ethyl). These new analyses were presented by Subodh Verma , M.D., Ph.D., a cardiac surgeon and Professor at the University of Toronto. HLS Therapeutics Inc.
shares T.HLS are trading down $0.03 at $15.47.
